Fu K K, Rayner P A, Lam K N
Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1473-8. doi: 10.1016/0360-3016(84)90371-7.
The combined effects of continuous low dose rate irradiation (CLDRI) and concurrent infusion of bleomycin, cyclophosphamide, cis-platinum, 5-fluorouracil, actinomycin D, and mitomycin C were studied in the SCC VII/SF tumor, a squamous cell carcinoma and the jejunal crypt cells in the mouse. For the SCC VII/SF tumor, enhanced cell killing was seen with each of the six drugs when infused concurrently with CLDRI; the greatest enhancement was seen with mitomycin C and cis-platinum. For the jejunal crypt cells, enhanced cell killing was seen primarily with bleomycin. At a dose of 20 Gy, the dose effect factor (DEF) ranged from 1.13-1.64 for the SCC VII/SF tumor and 0.92-1.19 for the jejunal crypt cells. Our results suggest a therapeutic gain with concurrent CLDRI and chemotherapy infusion for five of the six chemotherapeutic drugs studied with the exception of bleomycin.
在小鼠的SCC VII/SF肿瘤(一种鳞状细胞癌)和空肠隐窝细胞中,研究了连续低剂量率照射(CLDRI)与同时输注博来霉素、环磷酰胺、顺铂、5-氟尿嘧啶、放线菌素D和丝裂霉素C的联合效应。对于SCC VII/SF肿瘤,当六种药物中的每一种与CLDRI同时输注时,均可见细胞杀伤增强;丝裂霉素C和顺铂的增强作用最大。对于空肠隐窝细胞,主要是博来霉素导致细胞杀伤增强。在20 Gy的剂量下,SCC VII/SF肿瘤的剂量效应因子(DEF)范围为1.13 - 1.64,空肠隐窝细胞的剂量效应因子范围为0.92 - 1.19。我们的结果表明,除博来霉素外,在所研究的六种化疗药物中,有五种药物同时进行CLDRI和化疗输注可获得治疗增益。